Teva Pharmaceutical Industries Limited TEVA
Teva Pharmaceutical Industries Limited (NYSE: TEVA) is a CNS/neurology/psychiatry drug developer. Its lead program, BXCL-501 (dexmedetomidine sublingual film), is in Phase 3 for At-home use for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. Its next catalyst on record is WELTRUZA (olanzapine LAI): Commercial launch in U.S. (November 2026).
Upcoming catalysts
- November 2026WELTRUZA (olanzapine LAI) — Commercial launch in U.S.
WELTRUZA is expected to become available in the U.S. in the coming weeks
Next further out: BXCL-501 — FDA approval for at-home use for acute treatment of agitation (date not stated). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| BXCL-501 (dexmedetomidine) | At-home agitation treatment (schizophrenia/bipolar) | small molecule | Approved |
| ecopipam (EBS-101) | Tourette syndrome | small molecule | Phase 3 |
| duvakitug (anti-TL1A, TEV-'574) | Inflammatory Bowel Disease | antibody | Phase 3 |
| duvakitug (anti-TL1A, TEV-'574) | Hidradenitis Suppurativa | antibody | Phase 3 |
| DARI (TEV-'248, ICS/SABA) | Asthma | small molecule | Phase 3 |
| TEV-'292 (biosimilar to Eylea HD) | Ophthalmology (aflibercept biosimilar) | biologic-other | Phase 3 |
| Biosimilar to Entyvio IV (vedolizumab) | Inflammatory bowel disease | antibody | Phase 3 |
| Biosimilar to Entyvio SC (vedolizumab) | Inflammatory bowel disease | antibody | Phase 3 |
| Biosimilar to Simponi/Simponi Aria (golimumab) | Immunology/inflammation | antibody | Phase 3 |
| Biosimilar to Eylea (aflibercept) | Ophthalmology | protein/peptide | Phase 3 |
| Biosimilar to Xolair (omalizumab) | Respiratory/immunology | antibody | Phase 3 |
| Anti-IL-15 (TEV-'408) | Celiac disease | antibody | Phase 2 |
Recent results and decisions
- Nov 3, 2026accepted The U.S. FDA accepted the ecopipam NDA for review with an action date expected in Q1 2027.
The U.S. FDA accepted the ecopipam New Drug Application (NDA) for review, advancing a potential first-in-class selective D1 receptor anti-agonist for Tourette syndrome in the pediatric population, with an action date expected in Q1 2027.
Filing - Nov 3, 2026positive Teva reported positive Phase 2a results for anti-IL-15 in Celiac disease.
Teva reported positive Phase 2a results for anti-IL-15 (TEV-'408) in Celiac disease.
Filing - Nov 3, 2026discontinued Teva discontinued its phase 2 Multiple System Atrophy study of emrusolmin following an interim futility analysis.
Teva discontinued its phase 2 Multiple System Atrophy (MSA) study of emrusolmin (TEV-'286), following an interim futility analysis that indicated low probability of the study meeting its primary efficacy endpoint if continued.
Filing
1 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.